Board and Senior Management Team

Mr. Steve Harris, Chairman

Mr. Harris is an experienced Non-Executive Director with a range of private and public companies in the life sciences sector. He has a wide experience in fundraising and IPOs and an extensive international pharmaceutical and biotech experience with particular focus on business development and licensing.

Dr. Anthony Baxter, Chief Executive Officer

Dr. Baxter was formerly the founding CEO of Argenta Discovery Limited, a leading drug discovery services and proprietary therapeutics company backed by substantial venture capital investment. In less than four years from the company's start-up in 1999, he grew services revenue to over £9 million which included building a pipeline of novel therapeutic programmes. He then led the successful merger of the business with biotech company, Etiologics Limited. Prior to this, Dr. Baxter was Chief Scientific Officer of Oxford Asymmetry International plc and helped build the business from an early stage company to its flotation on the LSE and then to its eventual merger with Evotec in 2000 at a valuation of £316 million. Most recently, Dr. Baxter lead the turnaround of deltaDOT Limited, a proteomics / genomics platform technology company, which involved fundraising of £8.3 million. He is currently Non-Executive Chairman of Equinox Pharma Ltd., an Imperial College spin out company focussing on development of 'machine learning' for iterative and multi-parametric drug discovery projects.

Mr. John Dootson, Chief Financial Officer

Mr. Dootson has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, he has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. He has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for 1.1bn GBP. Mr. Dootson is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex Discovery in a management consultative role that has included all aspects of finance and reporting.